Kiendra 0.25 And 2 Mg 0.25 and 2 mg FC tablets
PDF Leaflet Revision Date: 30 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of secondary progressive multiple sclerosis (SPMS) with progressive disability.
Dosage (summary)
Start with 0.25 mg daily, titrate to 2 mg daily by day 6.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding.
Key Drug Interactions
- CYP2C9 inhibitors
- CYP3A4 inhibitors
- Anti-dysrhythmic medicines
Contraindications
- CYP2C9*3*3 genotype
- Active infections
- Macular oedema
Common side effects
- Headache
- Hypertension
- Dizziness
- Bradycardia
- Lymphopenia
Counselling Points
- Monitor for infections
- Avoid live vaccines
- Report visual disturbances
Serious warnings
- Risk of infections
- Macular oedema
- Bradycardia
- Liver function abnormalities
Important Disclaimer
The Kiendra 0.25 And 2 Mg 0.25 and 2 mg FC tablets professional information leaflet below is the property of Novartis Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
